The findings are based on the analysis of more than 3,000 genetic tests processed so far. The analysis indicates significant correlations between identified genetic predispositions, patients’ medical history, and laboratory test results. The results represent an initial step toward validating the use of genomic testing as a predictive tool in preventive healthcare.
The company also announced that its preventive genomic testing service will become available to the public starting March 20, with a price of RON 1,430, and will include consultation with a medical geneticist.
Among the study’s findings was the fact that participants with a high genetic risk for type 2 diabetes have significantly higher blood glucose levels compared with those with low genetic risk and up to twice the likelihood of developing the condition. The relationship also works in the opposite direction: participants with a low genetic risk have about half the probability of developing the disease compared with those with a higher risk. Similar correlations were also identified for other conditions analyzed, including cardiovascular and metabolic diseases.
The genomic analysis also highlighted potential genetic links between different conditions. Data suggests a shared genetic basis between type 1 diabetes and coeliac disease, indicating possible common immune mechanisms that may contribute to both illnesses. The study also points to possible shared mechanisms between obesity and chronic obstructive pulmonary disease (COPD), beyond known mechanical or metabolic factors.
According to the data analyzed so far, individuals in the study show on average approximately 2.2 elevated genetic predispositions for common conditions. Nearly 80% of participants have fewer than three elevated genetic risks, while less than 5% have six or more.
These findings represent the first signals of clinical validation for the analytical model used in the program. The model is based on polygenic risk scores (PRS) correlated with patient medical history and laboratory results. The relatively young cohort involved in the study, with an average age of 41, suggests that the genetic tool may identify disease risks before symptoms appear.
“Medicine is changing rapidly. The future of medicine is no longer only about treating diseases, but preventing them. By correlating genetic data with paraclinical medical information and each patient’s lifestyle, we can better identify risks before disease appears. This is the real paradigm shift: personalized prevention. The preliminary results represent the first measurable signals of local genetic particularities and are extremely encouraging. The fact that the associations between genetic risk scores and the real biological data of patients are so consistent confirms that we are on the right path. As we expand the cohort, we will obtain robust conclusions useful both for doctors and for health decision-makers. I believe that many Romanians will learn in the coming years what is best for them personally: what genetic advantages they were born with and what medical risks they need to pay closer attention to, whether certain foods suit them, whether their skin allows prolonged sun exposure, or which types of sport are most suitable for them. Medicine will undergo major changes in the coming years. Doctors will increasingly rely on technology—from robotic arms in operating rooms to AI support in imaging and genomics in prevention. I am proud that a private company in Romania has achieved results at such a level, positioning us at the forefront of preventive medicine in Europe and beyond. In about two weeks we will also make low-pass genetic testing available to the general public, an important first for Romania. Even so, we do not expect immediate monetization, but rather gradual adoption as preventive medicine becomes more integrated into routine medical practice and patient decision-making,” said Mihai Marcu, CEO and Chairman of the MedLife Group.
A key element of the Longevity100+ program is the integration of multiple types of medical data. The model correlates genomic information with patient medical history and laboratory test results, with plans to also integrate imaging investigations through its AI platform and lifestyle data collected in real time from compatible smart devices. Based on these sources, MedLife aims to generate comprehensive individual risk profiles for patients within its digital ecosystem.
“A simultaneous integration of four distinct types of data—from genomics and blood tests to imaging and biometric information—will allow us to build the most comprehensive individual risk profile currently available in Romania. To our knowledge, a model of this scale has not been implemented elsewhere in Europe and possibly even worldwide. This approach allows the early validation of associations between identified genetic risks and real biological indicators or medical history. In the coming months we will provide much more extensive information, as we already have several results that we hope to validate as soon as possible. We are surprised by the relatively small number of results available in many European countries with strong medical traditions,” Mihai Marcu added.
The program involves a multidisciplinary team of MedLife specialists including geneticists, molecular biologists, bioinformaticians, biostatisticians, and physicians from multiple medical specialties.
Large-scale genomics has been used in international research programs for several years, but integrating genetic data with medical history and clinical records remains a relatively new direction in medical practice, the company points out. Through its Longevity100+ program, MedLife aims to develop an integrated analytical model that is adapted to the realities of the Romanian healthcare system.
The preliminary results are based on data from more than 3,000 participants, representing about 75% of the total sample planned for the study. According to the researchers, the findings are not final and may change as the study expands to include additional participants and age groups.
MedLife Group is 12.8%-owned by Mihail Marcu, 14% by Mihaela Gabriela Cristescu and 13.2% by private pension fund Fondul de Pensii Administrat Privat NN Pensii, per stock market data. The company has a market capitalization of RON5.9 billion and its shares have traded 11% higher so far in 2026.